

Remarks

In the Advisory Action, the Examiner noted that Applicants' response of April 5, 2011 has not been entered because the amendments raise new issues that would require further consideration and/or search. The Examiner has further reiterated that claims 1, 2, 6-9, 40, 53, 58 and 59 are rejected; claims 10-36 and 41-52 are objected to; and claims 54-57 are withdrawn from consideration.


By this amendment, claims 1, 7 and 9 have been amended. Thus, claims 1, 2, 6-36, 40-55, 58 and 59 are pending in the application are pending in the application. No new subject matter has been inserted through these amendments. All of the amendments are fully supported by the specification.

More specifically, claims 1, 7 and 9 have been amended to limit one of the definitions of R¹ and R² together forms to "polycyclic aromatic ring" from "monocyclic or polycyclic aromatic." Claim 1 has further been amended to provide the definition of substituent on the 'Ar' to be 'alkyl' as defined in claim 10. As a result, all of the specific "monocyclic aromatic" moieties within the definition of R¹ and R² have been deleted from claims 7 and 9. Finally, a typographical error in claim 9 has also been corrected. The Examiner's rejections are respectfully traversed below.

Rejection Under 35 U.S.C. § 102(e)

Claims 1, 2, 6-9, 40, 53, 58 and 59 stand rejected under 35 U.S.C. 102(e) as being anticipated by Auerbach et al. (US 6,875,780).

In particular, Examiner alleges that "Auerbach discloses (Col. 75, l. 1-15) the following compound with the allowed variable assignments shown:



The Examiner considers R^1 and R^2 to represent the same group and together represent an aryl group” Office Action at page 3.

Although Applicants respectfully disagree with Examiner’s interpretation of instant claim 1 in light of Auerbach et al’s disclosure, solely for the purpose of expediting the prosecution of the instant case, it is submitted that independent claim 1, as amended, recites R^1 and R^2 together forms only “polycyclic aromatic ring,” thus rendering this rejection moot. Further, only two other dependent claims 7 and 9 which recite the definitions of R^1 and R^2 have similarly been amended. Therefore, it is respectfully submitted that none of the claims 1, 2, 6-9, 40, 53, 58 and 59 anticipates Auerbach et al. Accordingly, withdrawal of rejection as to claims 1, 2, 6-9, 40, 53, 58 and 59 is respectfully requested.

Claim Objections

Claims 10-36 and 41-52 stand objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

However, as noted above, it is believed that independent claim 1, as amended, overcomes all of the outstanding rejections as specifically articulated herein. More importantly, the limitations of claim 10 are further incorporated into claim 1, thus

obviating this objection. Thus, withdrawal of objection as to claims 10-36 and 41-52 is respectfully requested.

Allowable Subject Matter

Applicants acknowledge with much appreciation Examiner's indication of allowability of claims 10-36 and 41-52. For the reasons advanced above, it is also believed that claims 1, 2, 6-9, 40, 53, 58 and 59, as amended, are also in condition for allowance and such as action is earnestly solicited. More importantly, it is again emphasized that claim 1, as amended, does not recite any broader scope than otherwise allowable claim 10.

Rejoinder of Method claims 54 and 55

The Examiner has further noted that the method claims 54 and 55 will be considered for compliance with 35 U.S.C. 112, 102 and 103. However, as already noted above, withdrawn claims 54 and 55 depend directly upon independent claim 1 incorporating all of the limitations of claim 1, and further recite certain methods of treatments which are believed to be in condition for allowance. Therefore, it is respectfully submitted that claims 54 and 55 be rejoined and allowed with the rest of the pending claims.

Conclusions

In view of the above Remarks, it is respectfully submitted that claims 1, 2, 6-36, 40-55, 58 and 59 are now in condition for allowance and the early issuance of this case is respectfully requested. In the event the Examiner wishes to contact the undersigned regarding any matter, please call (collect if necessary) the telephone number listed below.

As noted above, Applicants concurrently submit herewith a request for continued examination (RCE) of this case and a petition for one-month extension of time to make this response timely. Applicants request the Commissioner to charge these fees and any other fees that are deemed necessary due to this submission to Deposit Account No. **50-**

Application Ser. No.: 10/575,122
Filing Date: April 7, 2006
Examiner: Zucker, Paul A.

3221 for Dr. Reddy's Laboratories, Inc., Bridgewater, NJ. Please credit any overpayment to Deposit Account No. **50-3221**.

Respectfully submitted,

May 24, 2011

/Balam Gupta/
Balam Gupta, Ph. D., J. D.
Registration No. 40,009
Attorney for Applicants

Dr. Reddy's Laboratories, Inc.
200 Somerset Corporate Blvd. 7th Floor
Bridgewater, NJ 08807
Tel. No. (908) 203-6508
Fax: (908) 203-6515
bgupta@drreddys.com